Editorial highlights next generation stem cell solutions optimized for heart failure therapy
Mont-Saint-Guibert, Belgium, – Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, announces today the referencing in the European Heart Journal, the official journal of the European Society of Cardiology, of lineage-specified cardioreparative stem cells as next generation regenerative biotherapeutics.
The editorial sets out the principles of regenerative cardiology, conceived to halt or reverse disease progression. As the heart has a limited self-renewal capacity, stem cell therapies are applied essentially as adjuvants to standard of care with the goal of fortifying reparative mechanisms. The editorial emphasizes that the inter-trial unevenness and inter-patient variability observed to date with conventional stem cell options has prompted the pursuit of optimization strategies, and lists optimization modalities under consideration, such as the principle to condition the myocardial environment prior to cell delivery, the principle to match regenerative cell source with the target organ, and the principle of rational design of cardioreparative biotherapeutics equipped with an upgraded regenerative potential.
The Cardio3 Biosciences’ C-Cure® product is the first-in-class cardioreparative biotherapeutics derived by the method of lineage-specification for use in heart failure. In the Phase II C-CURE clinical trial, heart failure patients were treated with C-Cure® which consists of patient-derived mesenchymal stem cells oriented into lineage-specified cardiogenic progenitor (cardiopoietic) cells. The C-CURE study indicates that the use of cardiopoietic cells is feasible and safe and documents significant benefit on Left Ventricular Ejection Fraction, a measure of heart function, versus baseline compared to no change for the control group treated with standard of care. C-Cure® is now tested in a Phase III study in Europe and Israel (CHART-1) and has been authorized by the FDA to be tested in the U.S (CHART-2). These phase III therapeutic studies highlight advances in regenerative science.
Dr Christian Homsy, CEO of Cardio3 BioSciences, comments: “Recognition in this editorial published in the prestigious European Heart Journal underscores Cardio3 BioSciences’ continuous advances and leadership in regenerative medicine, progressively bringing innovative science-driven therapeutic options to patients. By choosing the route of lineage specification, we lay the foundation for future standard of care in cardiology.”
